AstraZeneca's lung cancer combo trial with Imfinzi falls short on overall survival in patients with NSCLC who progressed after prior treatments; study tested ceralasertib in combo with Imfinzi.
On Monday, AstraZeneca Plc shared top-line results from the LATIFY Phase 3 trial of ceralasertib in combination with Imfinzi. The trial, conducted in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (AGAs), did not meet the primary endpoint of overall survival (OS) compared to standard-of-care docetaxel. The participants had experienced disease progression after prior immunotherapy and platinum-based chemotherapy. The combination of ceralasertib and Imfinzi demonstrated good tolerability, with a safety profile consistent with both medicines' known profiles, and no new safety concerns arose. At the same time, AstraZeneca and Daiichi Sankyo Co., Ltd.'s Enhertu (trastuzumab deruxtecan) earned FDA Breakthrough Designation.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments